艾伯维

AbbVie Triggers MACD Death Cross, Bollinger Bands Narrowing on 15-Minute Chart

UBS maintains Neutral rating on AbbVie with PT down to $230.

Evercore ISI Maintains Outperform on Abbvie, PT Down to $228

Abbvie

AbbVie: Market Misjudgment Uncovered

Abbvie: Morgan Stanley Maintains Overweight, PT Raised to $270 from $269

Catalyst<ul> <li>Most analysts rate ABBV Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Fund flows show net outflows across all order sizes indicating potential selling pressure.</li> <li>Recent Bearish Engulfing and Marubozu White signals indicate conflicting momentum patterns that may delay clarity on ABBV's direction.</li> <li>Analyst ratings show differences with two Buy and two Neutral ratings, suggesting uncertainty about ABBV's near-term outlook.</li></ul>

Key Factors

AbbVie Q4 2025 reported adjusted EPS of $2.71, exceeding Zacks' estimate of $2.66 and revenue of $16.62 billion, surpassing the $16.36 billion consensus. AbbVie shares fell 6.6% amid market volatility on February 4, closing at $210.77, despite analysts maintaining an average target price of $247.58. AbbVie expects 9.5% revenue growth in 2026, driven by blockbuster drug launches and pipeline momentum, with a projected 48.5% adjusted operating margin and $18.5 billion in free cash flow. CVS Caremark is replacing branded drugs, including AbbVie’s Humira, with biosimilar and generic alternatives on its formularies, effective April 1, 2026. AbbVie's immunology segment faces challenges, including a failed Phase 3 trial for VENCLEXTA in myelodysplastic syndrome, which impacts diversification strategy.

ABBV News